PACS Group, Inc. (PACS) stock intrinsic value fair value estimate & owner earnings analysis

PACS Group operates 321 skilled nursing and assisted living facilities in 17 western, midwestern and southern states (about 32,900 skilled nursing beds). It leases 268 of them under long-term leases and owns the real estate under some others. Revenue was $5.29 billion in 2025, up from $2.40 billion in 2022, almost all of it from buying or taking over facilities. Medicaid is the largest payer (roughly 57% of the mix), with Medicare and managed care providing the higher-paying skilled patients. How we measured earnings. We start from operating cash flow, strip out swings in working capital, and charge stock compensation and the capital spending needed just to keep facilities running. The business has several large working-capital items that make reported operating cash flow a poor guide to earnings: receivables ballooned in 2022-2023 (cash drain), while insurance reserves, payroll accruals and a growing refund liability ($181 million at the end of 2025, money collected that may have to be returned to payers) boosted 2024 and 2025 cash flow. We removed all of these. Purchases of facilities ($144 million in 2025, $283 million in 2024) are treated as acquisitions, not maintenance. On this basis owner earnings were about $1.27 per share in 2022, $0.97 in 2023, $0.29 in 2024 and $1.23 in 2025. 2024 is depressed by a one-time stock award of roughly $91 million triggered by the IPO, so we do not rely on it. 2022 and 2023 carry no stock compensation because the company was private, which flatters them. Adding back the roughly $40 million of annual cash interest to see the whole business before lenders gives about $1.30 per share (about $204 million a year), which is the level we use. It is set below 2025 because the pre-IPO years lacked a public-company stock-pay cost. Most recent results, and what we left out. First-half 2026 revenue was up about 10% ($2.85 billion) but operating income jumped from $129 million to $229 million and net income doubled to $157 million, with operating cash flow of $372 million against $203 million. Operating margin went from about 5% to about 8% on 10% revenue growth. We could not reconcile that margin jump from the filings available to us, and a margin expansion is not something we can count as secured, so none of it is in the base level. It is the single biggest thing that could prove us too low. Growth in the base: we credit none. The facility-buying engine is real and has run for years, but the acquisition returns are not disclosed and every acquisition costs cash that the anchor does not deduct, so we neither credit the growth nor charge the spending. The growth path is flat, not rising, versus last year's actual 2025 change, which is not meaningful because of the 2024 distortion; against 2023 business cash flow per share rose about 9% in total. Debt. At June 30, 2026 the company had about $246 million of borrowings (the $600 million Truist revolver was undrawn after $162 million drawn and repaid in the half), $154 million of finance leases and $164 million of cash. We treated about $100 million of cash as needed to run the business (roughly one week of costs), leaving net debt of about $335 million, or $2.07 per share. Operating lease obligations of roughly $3.0 billion are not subtracted, because the rent already runs through operating cash flow, but they make profits very sensitive to occupancy and reimbursement because the rent does not flex. Legal overhang. The company discloses Department of Justice civil investigative demands under the False Claims Act (including how patient assessments feed Medicare rates and use of the COVID-era hospital-stay waiver), a DOJ criminal-division subpoena (February 2025) covering waiver practices, Medicare Part B therapy billing and bad-debt claims, and an SEC investigation of its accounting and internal controls. A restatement and independent audit-committee investigation caused late filings in 2024-2025; the company has since filed everything and regained compliance with the NYSE, but says future delays could put the listing at risk. It states it cannot estimate any loss. These are in all three cases as cash settlements; a worse outcome such as exclusion from Medicare is not modeled in any case. Bear case: about $5.3 per share. A business worth about $1.20 billion less $335 million of net debt. Story: investigations conclude with $250 million of settlements and costs over two years; an occupancy and staffing shock of the 2020-2021 COVID kind, with the rent fixed, cuts cash flow to about $80 million for three years; afterwards, Medicaid payment limits in the 2025 federal budget law (it caps existing state directed payments at current levels) hold cash flow at about 60% of today's level, and the business fades 10% a year after year 15. Cash flow still covers its roughly $40 million interest bill every year. Base case: about $12.6 per share. A business worth about $2.37 billion less $335 million of net debt. Cash flow stays flat at about $204 million for 15 years, since reimbursement updates are not shown to outrun wage and rent inflation, with a $100 million settlement in years 2 and 3, then a gradual 10% annual fade because after that nothing nameable keeps it going. Bull case: about $20.0 per share. A business worth about $3.57 billion less $335 million of net debt. The first-half 2026 margin gain holds and cash flow is about $300 million a year for 15 years, with only a $50 million settlement, then the same fade. The ability to buy more facilities, and to exercise the purchase options on 37 leased facilities, is not credited. What would change our view: a filing that explains the 2026 margin step-up as durable (higher base), resolution of the DOJ and SEC matters on small terms, or conversely any charge, exclusion proceeding or further restatement. The earlier valuation (about $5.6, $9.6 and $15.4) was built on a different footing and is not directly comparable; what has changed in the business is two quarters of much stronger profits, a repaid revolver, and the same unresolved legal exposure. Why the margin-of-safety price is $8.00. Our confidence in the earnings level is moderate: the cash flow history is lumpy and short, and the biggest recent improvement is unexplained. The worst plausible outcome is a government finding that costs the company its Medicare and Medicaid participation; the facility leases and thin margins mean that outcome would leave little for owners, and no case models it. If we are wrong about the 2026 margin and cash flow falls back to the 2024 level, and the settlements are as large as in the bear case, the shares are worth roughly $4 to $5. A price of $8.00 values the whole enterprise at about 8 times the $204 million flat business cash flow, a 12 to 13% yield on a business that we assume does not grow, and the bear case still implies a loss of about a third from that price. The price assumes a three-to-five-year holding period for the legal matters to resolve; the business pays little to holders meanwhile, so any return must come from the cash the business generates and the narrowing of the legal discount.